Vectura Share Discussion Threads

[soundbuy] 14/3/2017 09:39

Break through 162p over coming weeks would set this up nicely........

[jopper74] 14/3/2017 08:22

150 broken.....lets hope this is now the sustained rise that we've all been waiting for

[fhmktg] 13/3/2017 16:27

Results next week- share price moving higher in anticipation?

[richtea1701] 13/3/2017 12:09

Chuggingtons

[pooroldboy55] 07/3/2017 15:27

Hi All im back from 12 very wet days in Limoges.
hope its not a POB day but looks that way,

[alexchry] 07/3/2017 14:38

Thanks for the info markf31. Unless there is a pick up later this afternoon, it looks like another pob sort of day or a grand old duke of York day, up in the morning, down in the afternoon.

[markf31] 07/3/2017 12:09

Alexchry - very normal for U.K. Plc's to have 2 ED's on Board. CEO and CFO standard

[soundbuy] 07/3/2017 12:06

Thin vols but hey ho.......

[alexchry] 07/3/2017 11:43

jopper-the chart is looking good, a close above 151 would make it even better. Only negative is the relatively small volume.I'm not sure what to make of the resignation and replacement not being on the board. There will then be eight board members which is OK but not sure if only two executives is enough but I'm not familiar with other board make-ups to know whether this ratio is common.

[popper joe] 07/3/2017 11:34

jopper, you can come here more often :-)

[jopper74] 07/3/2017 11:20

A good consistent rise, hopefully we can break the 150 mark and stay there....

[alexchry] 02/3/2017 10:44

SoundBuy-exactly what I was thinking. I would hope that this rise is shortly to be backed up by good news. If not, we've only around three weeks to wait for the results.

[soundbuy] 02/3/2017 10:41

Citigroup raising PT from 220.00p to 225.00p this am.

[soundbuy] 02/3/2017 10:30

Not a man for the charts but a break through 151p(ish) would look bullish.....

[boadicea] 02/3/2017 09:01

It has a spring in its step this morning. Hope it doesn't run out of puff before the close.

[cumnor] 01/3/2017 21:45

Thanks Qackers-tend to forget all those little SKP gems adding to VEC's bottom line-looks good.

[qackers] 01/3/2017 18:52

Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update.



01/03/2017 12:30pm
GlobeNewswire Inc.

Pacira Pharmaceuticals, Inc. (MM) (NASDAQ:PCRX)
Intraday Stock Chart
Today : Wednesday 1 March 2017


-- Phase 4 EXPAREL® study in total knee arthroplasty meets co-primary endpoints for pain control and opioid reduction against an active comparator --
-- EXPAREL net product sales up 11% year-over-year --
-- EXPAREL net product sales expected to be in the range of $290 to $310 million in 2017 --
-- Conference call today at 8:30 a.m. ET --


Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported financial results for 2016 and its outlook for 2017. The company is also announcing positive topline results for its Phase 4 study of EXPAREL® in total knee arthroplasty, or TKA.
“We made important progress in 2016 advancing our three-part EXPAREL growth strategy and setting the stage for continued success,” said Dave Stack, chief executive officer and chairman of Pacira. “We have multiple, major milestones on track for 2017, including the positive topline results reported today from our Phase 4 study in TKA. Our collaboration with DePuy Synthes is off to a strong start and will allow us to maximize these important data and broaden the use of EXPAREL as an opioid-sparing solution for prolonged postsurgical pain relief.”

[alexchry] 01/3/2017 08:39

Yesterday my warm feeling came back although the volume was low. As diesel says, the chart looks good but a finish over 146, which I was hoping for last week, will make it look even better. However, we must remember that whether the charts are good, bad or indifferent, it is the decision in May that is likely to have the most impact on the share price

[diesel] 28/2/2017 17:53

Chart looks good!

[fhmktg] 28/2/2017 16:31

News coming?

[carpadium] 28/2/2017 16:31

Spectacular by normal standards!

[richtea1701] 28/2/2017 16:28

Nice rise into close

[dontay] 24/2/2017 09:52

Excellent explanation Chop55, yes there are many different combinations/types of lung and airway breathing problems which are lumped under the general COPD heading and which will each require different forms of treatments/drugs... and as you quite rightly state the Asthma market alone for drugs like Flutiform is huge. Good though that VEC is at the forefront of expertise in the continuing fight to find treatments for the more serious forms of COPD.

[alexchry] 24/2/2017 09:25

Chop55-you may well be right so isn't it a surprise that the China COPD trial was completed before the China Asthma trial had even started.

[chop55] 24/2/2017 09:06

The problem with COPD is, that it is not a well defined disease. There are many different COPD entities. In the past the 'Asthma drugs' were repositioned and also tested in COPD and had a liitle effect. Most likely, because in the entire COPD population there were also some Asthamtics, or a small subgroup could be improved by the Asthma drugs. It is also known, that most stable COPD patients have no inflammation. So why should an anti-inflammatory drug has an effect? If Flutiform shows some effect in the Chinese population, which might well be, then the subgroup of inflammatory patients was big enough. But I would not expect a relevant effect in COPD with such kind of combination therapies any more.
New drugs are needed for the different COPD entities.
On the other hand the Asthma market for Flutiform is huge and not yet fully exploited.